At Amgen, our mission is to serve patients. As a science-based, patient-focused organisation, we discover and develop innovative therapies to treat serious illnesses.Our medicines have made a dramatic difference in the lives of millions.
Amgen is committed to patient safety and continually monitors the safety and quality of our products. If you want to contact Amgen for any of the following reasons, please call us on +44 (0)1223 436441 (UK and Ireland), Freephone: 1800 535160 (Ireland) and provide us with the details:
You think you may have experienced an adverse event ('side effect') after taking or using an Amgen product.
You think there may be a defect or quality issue with the Amgen product you have received.
You have a general medical information enquiry about your Amgen product.
If you are in the UK, you may also report adverse events or product defects directly to the Medicines and Healthcare products Regulatory Agency (MHRA) where you can also find reporting forms and information.
If you are in Ireland, you may also report adverse events or product defects to the Health Products Regulatory Authority (HPRA) where you can also find reporting forms and information.
Below you will find information on Amgen’s product portfolio. Prescribing information and patient information leaflets for each product can be downloaded through the links. These links direct you straight to the Electronic Medicines Compendium (eMC) and Medicines.ie websites; and provide information about all medicines available in the UK and Ireland respectively.
Please note that this information is specific to the UK and Ireland, and is not intended to replace the advice of a qualified doctor.
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
NEUPOGEN® (filgrastim) is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
The safety and efficacy of NEUPOGEN® are similar in adults and children receiving cytotoxic chemotherapy.
NEUPOGEN® is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an ANC of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of NEUPOGEN® is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
NEUPOGEN® is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
NEUPOGEN® - UK Summary of Product Characteristics and Patient Information Leaflets
NEUPOGEN® - Ireland Summary of Product Characteristics and Patient Information Leaflets
> Go back to top
Hypercholesterolaemia and mixed dyslipidaemia
Repatha® (evolocumab) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
- in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Homozygous familial hypercholesterolaemia
Repatha® is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.
The effect of Repatha on cardiovascular morbidity and mortality has not yet been determined.
Repatha® - UK Summary of Product Characteristics and Patient Information Leaflets
Repatha® - Ireland Summary of Product Characteristics and Patient Information Leaflets
> Go back to top
Total of 12 Products
Amgen is committed to patient safety and continually monitors the safety and quality of our products. Adverse events and product quality issues should be reported.
▼ This product is subject to additional monitoring.
For the UK - reporting forms and information can be found at http://yellowcard.mhra.gov.uk/
For Ireland - reporting forms and information can be found at http://www.hpra.ie/
Adverse events and product quality issues should also be reported to Amgen. To report a potential adverse event or quality issue with an Amgen product, or for medical information enquiries, please call +44 (0) 1223 436441 (UK and Ireland) Freephone: 1800 535160 (Ireland).